NCT07693894Recruiting
Innovative Ovarian Cancer Biomarker Assays
Multi-site, Multi-country Evaluation of Innovative Ovarian Cancer Biomarker Assays. (DISARM Clinical Study B-CSB)
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes. Recent research has focused on the development of blood-based tests, sometimes referred to as liquid biopsy tests, which aim to look for changes in the blood that could be linked to cancer. These tests are still under investigation and are not part of routine clinical care. The purpose of this study is to evaluate several blood-based ovarian cancer tests. This will be done by comparing test results from people who have ovarian cancer with results from people who do not have cancer. The study will also collect information from standard blood tests and genetic analyses to better understand how these results relate to ovarian cancer. This study is for research purposes only. The blood-based tests being evaluated are investigational and are not used to make medical decisions or diagnoses for women taking part in the study.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2080 (estimated)
- First submitted
- 5 Jul 2026
- Start date
- 3 Aug 2026
- Primary completion date
- Dec 2028
- Lead sponsor
- National and Kapodistrian University of Athens
- Diseases
- Ovarian cancer
- NCT number
- NCT07693894
What you commit to
- Study type: Observational
- Planned participants: 2080
- From 3 Aug 2026 to the primary completion date, Dec 2028
- 7 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior history and any treatment for malignancy
- Prior removal of either ovary for any reason
Other illness
- Any condition or circumstance that, in the opinion of the investigator, could interfere with the participant's ability to participate or comply with study requirements
Other
- Pregnant or lactating
Who the study is looking for
- EOC patients
- Women, trans men and non-binary people with female reproductive organs
- Aged ≥35 years\*
- Pathologically diagnosed, by biopsy, with EOC prior to surgical intervention or treatment
- Presenting with adnexal mass suspicious of OC on imaging and scheduled for surgical resection or biopsy (and subsequent confirmation of EOC)
- Able to give informed consent
- Healthy controls
- Women, trans men and non-binary people with female reproductive organs
- Aged ≥35 years
- No cancer history
- Able to give informed consent
Age in the registry: 35 years to - · Sex: Female · Accepts healthy volunteers
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fakultni nemocnice Bulovka Coordinator of this site? Confirm its status | Prague | Czechia | Recruiting |
| Vseobecna fakultni nemocnice v Praze Coordinator of this site? Confirm its status | Prague | Czechia | Recruiting |
| Imperial College Healthcare Nhs Trust - Hammersmith Hospital Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
| Dept of Clinical Therapeutics, Alexandra Hospital Coordinator of this site? Confirm its status | Athens | Greece | Recruiting |
| National Centre for Scientific Research Demokritos Coordinator of this site? Confirm its status | Athens | Greece | Recruiting |
| Lithuanian University of Health Sciences Coordinator of this site? Confirm its status | Kaunas | Lithuania | Not yet recruiting |
| Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E. Coordinator of this site? Confirm its status | Lisbon | Portugal | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.